A new trading day began on Monday, with Taysha Gene Therapies Inc (NASDAQ: TSHA) stock price up 10.68% from the previous day of trading, before settling in for the closing price of $2.06. TSHA’s price has ranged from $1.19 to $4.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 129.39%. Meanwhile, its annual earnings per share averaged 61.46%. With a float of $153.61 million, this company’s outstanding shares have now reached $186.96 million.
Considering the fact that the conglomerate employs 52 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 90.01%, operating margin of -880.73%, and the pretax margin is -229.67%.
Taysha Gene Therapies Inc (TSHA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Taysha Gene Therapies Inc is 25.05%, while institutional ownership is 69.89%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 61.46% per share during the next fiscal year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Here are Taysha Gene Therapies Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 42.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.03, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Compared to the last year’s volume of 2.63 million, its volume of 10.86 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 70.02%. Additionally, its Average True Range was 0.24.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 75.69%, which indicates a significant increase from 75.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 202.37% in the past 14 days, which was higher than the 92.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.98, while its 200-day Moving Average is $2.40. Nevertheless, the first resistance level for the watch stands at $2.39 in the near term. At $2.50, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.67. If the price goes on to break the first support level at $2.12, it is likely to go to the next support level at $1.95. Should the price break the second support level, the third support level stands at $1.84.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
With a market capitalization of 424.04 million, the company has a total of 204,943K Shares Outstanding. Currently, annual sales are 15,450 K while annual income is -111,570 K. The company’s previous quarter sales were 1,110 K while its latest quarter income was -20,930 K.
